FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma
Perla Pucci, Charlotte Barrett, Ricky M. Trigg, Jamie D. Matthews, Marcus Borenäs, Michaela Schlederer, Leila Jahangiri, Lucy Hare, Christopher Steel, Emily R. James, Nina Prokoph, Lukas Kenner, Ruth Helen Palmer, Bengt Hallberg, G. A. Amos Burke, Suzanne Dawn Turner
This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.
bioRxiv · Sep 5, 2024 · PreprintCancer Biology